Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Activation of latent HIV using drug-loaded nanoparticles.

Kovochich M, Marsden MD, Zack JA.

PLoS One. 2011 Apr 5;6(4):e18270. doi: 10.1371/journal.pone.0018270.

2.

HIV latency in the humanized BLT mouse.

Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Bristol G, An DS, Zack JA.

J Virol. 2012 Jan;86(1):339-47. doi: 10.1128/JVI.06366-11. Epub 2011 Nov 9.

3.

Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.

Martínez-Bonet M, Clemente MI, Álvarez S, Díaz L, García-Alonso D, Muñoz E, Moreno S, Muñoz-Fernández MÁ.

Antiviral Res. 2015 Nov;123:163-71. doi: 10.1016/j.antiviral.2015.09.014. Epub 2015 Sep 30.

PMID:
26427554
4.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.

5.

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF.

Nat Med. 2014 Apr;20(4):425-9. doi: 10.1038/nm.3489. Epub 2014 Mar 23.

6.

Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.

Miller LK, Kobayashi Y, Chen CC, Russnak TA, Ron Y, Dougherty JP.

Retrovirology. 2013 Oct 24;10:120. doi: 10.1186/1742-4690-10-120.

7.

Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.

Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF.

J Antimicrob Chemother. 2014 Jan;69(1):28-33. doi: 10.1093/jac/dkt338. Epub 2013 Sep 1.

8.

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.

Martínez-Bonet M, Clemente MI, Serramía MJ, Muñoz E, Moreno S, Muñoz-Fernández MÁ.

Sci Rep. 2015 Nov 13;5:16445. doi: 10.1038/srep16445.

9.

PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread.

Tang X, Liang Y, Liu X, Zhou S, Liu L, Zhang F, Xie C, Cai S, Wei J, Zhu Y, Hou W.

Nanoscale Res Lett. 2015 Dec;10(1):413. doi: 10.1186/s11671-015-1112-z. Epub 2015 Oct 22.

10.

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-21. doi: 10.1016/j.ebiom.2015.11.047. eCollection 2016 Jan.

11.

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.

PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.

12.

Modeling the timing of antilatency drug administration during HIV treatment.

Petravic J, Martyushev A, Reece JC, Kent SJ, Davenport MP.

J Virol. 2014 Dec;88(24):14050-6. doi: 10.1128/JVI.01701-14. Epub 2014 Sep 24.

13.
14.

From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Shan L, Siliciano RF.

Bioessays. 2013 Jun;35(6):544-52. doi: 10.1002/bies.201200170. Epub 2013 Apr 24. Review.

15.

Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, Liu JO, Siliciano RF.

J Antimicrob Chemother. 2012 Feb;67(2):398-403. doi: 10.1093/jac/dkr496. Epub 2011 Dec 7.

16.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V.

PLoS Pathog. 2013;9(12):e1003834. doi: 10.1371/journal.ppat.1003834. Epub 2013 Dec 26.

17.

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF.

J Clin Invest. 2009 Nov;119(11):3473-86. doi: 10.1172/JCI39199. Epub 2009 Oct 1.

18.

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo.

Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, Quinn TC, Siliciano RF.

J Virol. 2003 Jul;77(13):7383-92.

19.

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS.

J Infect Dis. 2007 Jun 15;195(12):1762-4. Epub 2007 May 2.

PMID:
17492591
20.

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(12):6060-4. doi: 10.1128/JVI.02033-10. Epub 2011 Apr 6.

Supplemental Content

Support Center